Rodent models of amyotrophic lateral sclerosis

Research output: Contribution to journalArticle

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (~40% to 50% of fALS and ~10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.

Original languageEnglish (US)
Pages (from-to)5.67.1-5.67.21
JournalCurrent protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) ... [et al.]
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Amyotrophic Lateral Sclerosis
Rodentia
Motor Neuron Disease
RNA
Muscular Atrophy
Oligodendroglia
Autophagy
Microglia
Motor Neurons
Neuroglia
Astrocytes
Paralysis
Genes
Homeostasis
Nucleotides
Central Nervous System
Animal Models
Phenotype
Mutation
Research

Keywords

  • Aberrant protein homeostasis
  • Amyotrophic Lateral Sclerosis
  • Glia
  • Motor neuron
  • RNA processing alterations
  • Rodent models

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{f285538615f44e11a48e88e9e5ff877a,
title = "Rodent models of amyotrophic lateral sclerosis",
abstract = "Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10{\%}) or sporadic ALS (sALS, 90{\%}). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15{\%} of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (~40{\%} to 50{\%} of fALS and ~10{\%} of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.",
keywords = "Aberrant protein homeostasis, Amyotrophic Lateral Sclerosis, Glia, Motor neuron, RNA processing alterations, Rodent models",
author = "Thomas Philips and Rothstein, {Jeffrey D}",
year = "2015",
doi = "10.1002/0471141755.ph0567s69",
language = "English (US)",
volume = "2015",
pages = "5.67.1--5.67.21",
journal = "Current Protocols in Pharmacology",
issn = "1934-8282",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Rodent models of amyotrophic lateral sclerosis

AU - Philips, Thomas

AU - Rothstein, Jeffrey D

PY - 2015

Y1 - 2015

N2 - Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (~40% to 50% of fALS and ~10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.

AB - Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (~40% to 50% of fALS and ~10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non-SOD1-mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non-cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models.

KW - Aberrant protein homeostasis

KW - Amyotrophic Lateral Sclerosis

KW - Glia

KW - Motor neuron

KW - RNA processing alterations

KW - Rodent models

UR - http://www.scopus.com/inward/record.url?scp=84949228570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949228570&partnerID=8YFLogxK

U2 - 10.1002/0471141755.ph0567s69

DO - 10.1002/0471141755.ph0567s69

M3 - Article

VL - 2015

SP - 5.67.1-5.67.21

JO - Current Protocols in Pharmacology

JF - Current Protocols in Pharmacology

SN - 1934-8282

ER -